CoChat

Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Open access
Goubet, Anne-Gaëlle, Lordello, Leonardo, Alves Costa Silva, Carolina, Peguillet, Isabelle, Gazzano, Marianne, Mbogning-Fonkou, Maxime Descartes, Thelemaque, Cassandra, Lebacle, Cédric, Thibault, Constance, Audenet, François, Pignot, Géraldine, Gravis, Gwenaelle, Helissey, Carole, Campedel, Luca, Roupret, Morgan, Xylinas, Evanguelos, Ouzaid, Idir, Dubuisson, Agathe, Mazzenga, Marine, Flament, Caroline, Ly, Pierre, Marty, Virginie, Signolle, Nicolas, Sauvat, Allan, Sbarrato, Thomas, Filahi, Mounia, Davin, Caroline, Haddad, Gabriel, Bou Khalil, Jacques, Bleriot, Camille, Danlos, François-Xavier, Dunsmore, Garett, Mulder, Kevin, Silvin, Aymeric, Raoult, Thibault, Archambaud, Baptiste, Belhechmi, Shaima, Gomperts Boneca, Ivo, Cayet, Nadège, Moya-Nilges, Maryse, Mallet, Adeline, Daillere, Romain, Rouleau, Etienne, Radulescu, Camelia, Allory, Yves, Fieschi, Jacques, Rouanne, Mathieu, Ginhoux, Florent, Le Teuff, Gwénaël, Derosa, Lisa, Marabelle, Aurélien, Van Dorp, Jeroen, Van Dijk, Nick, Van Der Heijden, Michiel S., Besse, Benjamin, Andre, Fabrice, Merad, Miriam, Kroemer, Guido, Scoazec, Jean-Yves, Zitvogel, Laurence, Loriot, Yohann · 2022 · Cancer Discovery

Published version of a preprint

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Abstract

Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. SIGNIFICANCE: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-22-0201

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

2 retracted

Show all 85 references

Cited by

See all 88

Metadata

Authors
Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., Pignot, G., Gravis, G., Helissey, C., Campedel, L., Roupret, M., Xylinas, E., Ouzaid, I., Dubuisson, A., Mazzenga, M., Flament, C., Ly, P., Marty, V., Signolle, N., Sauvat, A., Sbarrato, T., Filahi, M., Davin, C., Haddad, G., Bou Khalil, J., Bleriot, C., Danlos, F.-X., Dunsmore, G., Mulder, K., Silvin, A., Raoult, T., Archambaud, B., Belhechmi, S., Gomperts Boneca, I., Cayet, N., Moya-Nilges, M., Mallet, A., Daillere, R., Rouleau, E., Radulescu, C., Allory, Y., Fieschi, J., Rouanne, M., Ginhoux, F., Le Teuff, G., Derosa, L., Marabelle, A., Van Dorp, J., Van Dijk, N., Van Der Heijden, M. S., Besse, B., Andre, F., Merad, M., Kroemer, G., Scoazec, J.-Y., Zitvogel, L., & Loriot, Y.
Affiliations
  • Inserm (FR)
  • 1Gustave Roussy, Villejuif, France.
  • 6Urology Department, University Hospital of Bicêtre-Paris Sud-Saclay University, Le Kremlin Bicêtre, Paris, France.
  • Université Paris Cité (FR)
  • Institut Paoli-Calmettes (FR)
  • 10Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.
  • 11Military Hospital Begin, Saint-Mandé, France.
  • Sorbonne Université (FR)
  • 13GRC 5 Predictive Onco-Uro, Sorbonne University, Department of Urology, AP-HP, Pitie-Salpetriere Hospital, Paris, France.
  • Hôpital Bichat-Claude-Bernard (FR)
  • 14Department of Urology, Bichat-Claude Bernard Hospital, Paris University, Paris France.
  • 18Veracyte, Marseille, France.
  • Institut de Recherche pour le Développement (FR)
  • 19Aix-Marseille University, IRD, APHM, MEPHI, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
  • Université Paris-Saclay (FR)
  • Institut Gustave Roussy (FR)
  • 22Institut Pasteur, Université de Paris, CNRS UMR2001, INSERM U1306, Unité de Biologie et Génétique de la paroi bactérienne, Paris, France.
  • Institut Pasteur (FR)
  • 23Core Facility Ultrastructural BioImaging Core Facility, Institut Pasteur, Paris France.
  • 24EverImmune, Gustave Roussy, Villejuif, France.
  • 25Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
  • Université de Versailles Saint-Quentin-en-Yvelines (FR)
  • Agency for Science, Technology and Research (SG)
  • 31Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • 32Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • 35The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Corresponding author
Zitvogel, Laurence
Venue
Cancer Discovery
Published
2022-08-05
Volume
12
Issue
10
Pages
2280-2307
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4289936629
Cited by
86
References
85
Citations by year
2026: 18 · 2025: 18 · 2024: 33 · 2023: 16 · 2022: 1
FWCI
7.42
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
Funders
  • Fondation pour la Recherche Médicale (FDM201806006036)
  • RHU5 (ANR-21-RHUS-0017)
  • RHU Torino Lumiere (ANR-16-RHUS-0008)
  • ANR (19-CE15-0029-01)
  • EU-H2020 (825410)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
muscle-invasive bladder cancer, neoadjuvant pembrolizumab, anti-PD-1 therapy, T follicular helper cells, CXCL13, Escherichia coli, tumor-infiltrating immune cells, tertiary lymphoid structures, PD-L1, treatment response biomarkers, progression-free survival
MeSH terms
Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Escherichia coli, T-Lymphocytes, Helper-Inducer, Humans, Immunoglobulin G, Muscles, Treatment Outcome, Neoadjuvant Therapy, Chemokine CXCL13, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-0201
The paper
Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., Pignot, G., Gravis, G., Helissey, C., Campedel, L., Roupret, M., Xylinas, E., Ouzaid, I., Dubuisson, A., Mazzenga, M., . . . Loriot, Y. (2022). Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-0201

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.